Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia (BAITP)

Peking University People’s Hospital is conducting a phase II trial evaluating Baricitinib, a Janus kinase inhibitor, in steroid-resistant or relapsed ITP. This single-arm, open-label study is recruiting participants aged 18-70 with primary ITP, a platelet count <30,000/µl for over 6 months and have failed at least one ITP treatment. Participants with secondary ITP, active or previous malignancy, active infection, are pregnant, or experienced a thrombotic event in the previous 24 weeks will be unable to enrol in the study.



back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo